What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.
ApexOnco Front Page
Recent articles
16 September 2024
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
14 September 2024
Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.
14 September 2024
The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.
14 September 2024
The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.
14 September 2024
Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.
14 September 2024
But the Galaxies Lung-201 trial features notable omissions, plus toxicity.
14 September 2024
Relativity-104 is revealed as a failure, and the phase 3 it just spawned could fail too.
Recent Quick take
- 2 September 2024
- 30 August 2024
- 29 August 2024
- 29 August 2024
- 28 August 2024
- 27 August 2024
- 22 August 2024
- 21 August 2024
- 20 August 2024
- 20 August 2024